Pharming Group (PHAR) Scheduled to Post Quarterly Earnings on Thursday
by Doug Wharley · The Cerbat GemPharming Group (NASDAQ:PHAR – Get Free Report) is scheduled to issue its quarterly earnings data before the market opens on Thursday, October 24th. Analysts expect the company to announce earnings of $0.01 per share for the quarter. Pharming Group has set its FY 2024 guidance at EPS.
Pharming Group (NASDAQ:PHAR – Get Free Report) last announced its earnings results on Thursday, August 1st. The company reported ($0.01) EPS for the quarter. The firm had revenue of $74.09 million for the quarter, compared to analysts’ expectations of $71.95 million. Pharming Group had a negative net margin of 4.65% and a negative return on equity of 5.69%. During the same quarter last year, the business earned $0.02 earnings per share. On average, analysts expect Pharming Group to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.
Pharming Group Stock Up 0.3 %
Shares of NASDAQ:PHAR opened at $8.94 on Wednesday. Pharming Group has a 1 year low of $6.65 and a 1 year high of $13.20. The firm’s 50-day moving average is $7.97 and its two-hundred day moving average is $8.58. The firm has a market capitalization of $606.18 million, a PE ratio of -47.03 and a beta of 0.15. The company has a debt-to-equity ratio of 0.40, a current ratio of 3.39 and a quick ratio of 2.65.
Wall Street Analyst Weigh In
Separately, HC Wainwright reiterated a “buy” rating and issued a $37.00 price objective on shares of Pharming Group in a research note on Thursday, October 10th.
Read Our Latest Research Report on Pharming Group
About Pharming Group
Pharming Group N.V., a biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally. The company offers RUCONEST, a recombinant C1 esterase inhibitor for the treatment of acute attacks in adult and adolescent patients with acute hereditary angioedema (HAE); and Joenja (leniolisib), an oral small molecule PI3K? inhibitor for the treatment of activated phosphoinositide 3-kinase delta syndrome.
Read More
- Five stocks we like better than Pharming Group
- Biggest Stock Losers – Today’s Biggest Percentage Decliners
- How Verizon Could Offer Stress-Free Double-Digit Returns in 2025
- What Are Trending Stocks? Trending Stocks Explained
- Can Roche Challenge Lilly and Novo in the Weight Loss Market?
- Why Invest in 5G? How to Invest in 5G Stocks
- Roblox Stock: Key Metrics Surge, Is This the Perfect Entry?